: The past 20 years of stroke research have shown that acute stroke is a treatable disease but reversibility of damage is tightly time dependent. It is possible to find exciting treatment strategies in the laboratory, but difficult to design and carry out clinical research to translate them into clinical benefit. Even when effective therapy is demonstrated, there are unexpectedly huge impediments to having it adopted and widely available. Given the massive public health problem of stroke in our aging population, these conundrums demand our attention. They are the foci of the UT Stroke Program and the SPOTRIAS PA. The thematic model of our Stroke Program is to develop improved treatment of acute stroke by 1) laboratory investigation into the biology of stroke, 2) clinical investigation of new therapies based on these laboratory studies, and 3) assessment of outcome and improved application of effective therapies. This Program Project has three broad Specific Aims: 1. Development of effective new acute stroke therapies through clinical research projects based on biological principles of ischemic injury learned in the laboratory. We will describe four planned Phase 1 or 2 Clinical trials of novel acute interventions; caffeinol for neuroprotection, the thrombin inhibitor argatroban to enhance reperfusion after TPA, ultrasound to augment clot lysis after TPA, and constraint induced movement therapy to amplify recovery. These projects require the multidisciplinary involvement of EMS, Emergency Medicine, Radiology, Critical Care, Ultrasound, and Rehabilitation. 2. Application of more efficient and widespread acute stroke treatment by improving the organization of local and regional stroke centers using cutting-edge telemedicine technology, and evaluation of a novel middle-school educational initiative to help solve the problem of inadequate public knowledge. 3. Development of Clinical, Statistical, Human Tissue, and Training """"""""Cores"""""""" that will facilitate the accomplishment of Specific Aims # 1 and 2. These cores will also provide important new resources for fellowship training.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1-SRB-K (01))
Program Officer
Janis, Scott
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center Houston
Schools of Medicine
United States
Zip Code
Berekashvili, Ketevan; Soomro, Jazba; Shen, Loren et al. (2018) Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study). J Stroke Cerebrovasc Dis 27:3647-3651
Cai, Chunyan; Rahbar, Mohammad H; Hossain, Md Monir et al. (2017) A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research. Contemp Clin Trials Commun 7:11-17
Barreto, Andrew D; Ford, Gary A; Shen, Loren et al. (2017) Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke 48:1608-1616
Ifejika, Nneka Lotea; Noser, Elizabeth Anne; Grotta, James C et al. (2016) Swipe out Stroke: Feasibility and efficacy of using a smart-phone based mobile application to improve compliance with weight loss in obese minority stroke patients and their carers. Int J Stroke 11:593-603
Lyden, Patrick; Hemmen, Thomas; Grotta, James et al. (2016) Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). Stroke 47:2888-2895
McDonald, Mark M; Wetzel, Jeremy; Fraser, Stuart et al. (2016) Thrombelastography does not predict clinical response to rtPA for acute ischemic stroke. J Thromb Thrombolysis 41:505-10
Vahidy, F S; Rahbar, M H; Lal, A P et al. (2015) Patient refusal of thrombolytic therapy for suspected acute ischemic stroke. Int J Stroke 10:882-6
Schlick, Konrad H; Hemmen, Thomas M; Lyden, Patrick D (2015) Seizures and Meperidine: Overstated and Underutilized. Ther Hypothermia Temp Manag 5:223-7
Ifejika, Nneka L; Vahidy, Farhaan; Aramburo-Maldonado, Linda A et al. (2015) Acute Intravenous Tissue Plasminogen Activator Therapy does not Impact Community Discharge after Inpatient Rehabilitation. Int J Neurorehabil 2:
Huang, Richard S P; McDonald, Mark M; Wetzel, Jeremy S et al. (2015) Clot Strength as Measured by Thrombelastography Correlates with Platelet Reactivity in Stroke Patients. Ann Clin Lab Sci 45:301-7

Showing the most recent 10 out of 72 publications